SOHO 2022 Tenth Annual Meeting
Avatar

SOHO 2022: Bispecific T-Cell Engagers - Early Data and Where Will We Use Them?

By SOHO 2022 Tenth Annual Meeting FEATURING Robert Z. Orlowski
October 14, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

14:48
Seagen

Impact on the Future of First Line Treatment in Stage III/IV Classic…

Feat. A. Forman

Featured Video

17:12
Seagen

Strategies for Managing Toxicities Associated with a First Line Trea…

Feat. A. Forman

Related Content

AUTOPLAY
20:19
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Highlights of Hematologic Malignancies - …

Feat. A. Paulus
12:38
SOHO 2022 Tenth Annual Meeting

SOHO 2022 DEBATE: Bispecific Antibodies vs. CAR-T for R/R MM - Defen…

Feat. S. Usmani
04:08
CancerGRACE

CAR T-Cell Therapy Side Effects for Blood Cancers

Feat. A. Goodman
15:24
Michael Soulen

Interventional Delivery of CAR-T Therapy

31:51
Indy Hematology Review

Treating Multiple Myeloma: The Cure Is Within Reach - Goals of Curre…

Feat. K. Anderson
30:59
Houston Methodist Hospital

Overview of Advances in Multiple Myeloma

Feat. S. Ganguly
44:49
Dana-Farber Cancer Institute

Recent Updates in Multiple Myeloma

Feat. K. Anderson
24:12
SIR 2022 Coverage

New and Evolving Clinical Trials: Embolotherapy

Feat. M. Soulen
09:18
ESMO 2022 Conference Coverage

ESMO 2022 Congress Highlights: Hematological Malignancies

Feat. I. Glimelius
21:38
Rahul Banerjee

CAR-T Therapy in Myeloma: What's Here and What's Coming So…

33:11
Total Health

Bispecific Antibodies and CAR T-Cells for NHL: Challenges and Opport…

Feat. K. Komanduri
06:41
Hamza Hashmi

Idecabtagene Vicleucel vs. Ciltacabtagene Autoleucel: A Sophie'…

21:16
UChicago Medicine

Myeloma 2022: Challenges and Path Forward

Feat. A. Jakubowiak
10:09
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Next Questions for MM in the Coming 5-10 Years

Feat. T. Martin
47:04
Dana-Farber Cancer Institute

Future Directions for Novel & Next Gen Therapy in the Management…

Feat. P. Richardson
18:27
Indy Hematology Review

DEBATE: Why Not to Transplant When MRD Has Been Achieved After Initi…

Feat. J. Mikhael
32:03
Indy Hematology Review

Emerging and Current Treatment of MM: What Should We Know and What S…

Feat. K. Anderson
42:37
University of Colorado Department of Medicine

Multiple Myeloma in 2023: An Oncological Success Story

Feat. P. Forsberg
21:13
Total Health

The Role of CAR T-Cell Therapy in DLBCL and B-ALL

Feat. B. Dholaria
06:16
ASH 2022 Conference Coverage

U.S. Myeloma CAR-T Consortium Real World Experience: Factors Associa…

Feat. H. Hashmi